Inhibition of the OR5B21 olfactory receptor gene significantly decreased the metastasis of breast cancer cells to the brain, lungs, and bones, researchers report.
Dasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer's associated gene.
Combining Disulfiram, a medication commonly used to treat chronic alcoholism, with copper ions kills medulloblastoma cancer cells and prevents new ones from growing.
Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.
A new study reports a strong association between high levels of physical activity and the ability to maintain cognitive function in breast cancer patients who received chemotherapy.